AR083610A1 - COMPUESTOS TRICICLICOS COMO INHIBIDORES DE PROSTAGLANDINA E SINTASA-1 MICROSOMICA (mPGES-1) - Google Patents
COMPUESTOS TRICICLICOS COMO INHIBIDORES DE PROSTAGLANDINA E SINTASA-1 MICROSOMICA (mPGES-1)Info
- Publication number
- AR083610A1 AR083610A1 ARP110104018A ARP110104018A AR083610A1 AR 083610 A1 AR083610 A1 AR 083610A1 AR P110104018 A ARP110104018 A AR P110104018A AR P110104018 A ARP110104018 A AR P110104018A AR 083610 A1 AR083610 A1 AR 083610A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- hydrogen
- different
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 101710096361 Prostaglandin E synthase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 229910003827 NRaRb Inorganic materials 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- -1 cyano, hydroxyl Chemical group 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000000160 oxazolidinyl group Chemical group 0.000 abstract 1
- 125000005968 oxazolinyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000001984 thiazolidinyl group Chemical group 0.000 abstract 1
- 125000002769 thiazolinyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
Abstract
Composición farmacéutica y uso para el tratamiento del dolor, asma, osteoartritis y enfermedades neurodegenerativas, entre otras.Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1), o una sal farmacéuticamente aceptable del mismo, donde, A es fenilo o piridinilo; Y se selecciona entre -CR3R4-, y -NR4-; L es una unión o se selecciona entre -(CH2)- y -C(O)-; R2 se selecciona entre C(O)ORa, C(O)NRaRb y un heterociclo sustituido o no sustituido seleccionado entre morfolinilo, oxazolinilo, oxazolidinilo, oxadiazolilo, tiazolinilo y tiazolidinilo; R3 y R4, que pueden ser iguales o diferentes, se seleccionan en forma independiente entre hidrógeno y alquilo C1-4; R5 y R6, que pueden ser iguales o diferentes, se seleccionan en forma independiente entre hidrógeno, alquilo C1-4 y cicloalquilo C3-6; en cada caso R8, que puede ser el mismo o distinto, se selecciona en forma independiente entre halógeno, nitro, ciano, hidroxilo, alquilo sustituido o no sustituido y haloalquilo sustituido o no sustituido; en cada caso, Ra y Rb que pueden ser iguales o diferentes, se seleccionan en forma independiente entre hidrógeno, alquilo sustituido o no sustituido, haloalquilo sustituido o no sustituido, haloalcoxi sustituido o no sustituido, alcoxialquilo sustituido o no sustituido, hidroxialquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, cicloalquilalquilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heterociclo sustituido o no sustituido, heterociclilalquilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, heteroarilalquilo sustituido o no sustituido, -(CH2)pNRxRy, y -(CH2)pCHRxRy; o Ra y Rb junto con el átomo al cual están unidos, pueden formar un anillo; sustituido o no sustituido; el anillo puede contener opcionalmente uno o más heteroátomos seleccionados entre O, N o S; en cada caso, Rx y Ry, que pueden ser iguales o diferentes, se seleccionan en forma independiente entre hidrógeno, alquilo C1-4, arilo sustituido o no sustituido y arilalquilo sustituido o no sustituido; Rz se selecciona entre hidrógeno, alquilo C1-4, y alcoxialquilo sustituido o no sustituido; la línea punteada [- -] en el anillo representa un enlace opcional; con la condición de que cuando la línea punteada [- -] en el anillo representa una unión, luego R4 y R5 están ambos ausentes; ‘m’ es un entero entre 0 y 5, ambos inclusive; y ‘p’ es un entero entre 0 y 6, ambos inclusive.
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3009MU2010 | 2010-10-29 | ||
| US41640010P | 2010-11-23 | 2010-11-23 | |
| IN9MU2011 | 2011-01-03 | ||
| US201161436674P | 2011-01-27 | 2011-01-27 | |
| IN1121MU2011 | 2011-04-01 | ||
| US201161479463P | 2011-04-27 | 2011-04-27 | |
| IN1632MU2011 | 2011-06-02 | ||
| US201161498758P | 2011-06-20 | 2011-06-20 | |
| IN2099MU2011 | 2011-07-25 | ||
| US201161523970P | 2011-08-16 | 2011-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083610A1 true AR083610A1 (es) | 2013-03-06 |
Family
ID=44913260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110104018A AR083610A1 (es) | 2010-10-29 | 2011-10-28 | COMPUESTOS TRICICLICOS COMO INHIBIDORES DE PROSTAGLANDINA E SINTASA-1 MICROSOMICA (mPGES-1) |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8519149B2 (es) |
| AR (1) | AR083610A1 (es) |
| TW (1) | TW201305178A (es) |
| WO (1) | WO2012055995A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR084174A1 (es) | 2010-12-21 | 2013-04-24 | Lilly Co Eli | Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica |
| WO2013118071A1 (en) * | 2012-02-09 | 2013-08-15 | Glenmark Pharmaceuticals S.A. | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS |
| WO2013153535A1 (en) | 2012-04-13 | 2013-10-17 | Glenmark Pharmaceuticals S.A. | TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS |
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| WO2014149819A1 (en) | 2013-03-14 | 2014-09-25 | Kalyra Pharmaceuticals, Inc. | Bicyclic analgesic compounds |
| WO2014167444A1 (en) | 2013-04-08 | 2014-10-16 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS |
| WO2015059618A1 (en) | 2013-10-22 | 2015-04-30 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS |
| CN108947867A (zh) | 2013-12-12 | 2018-12-07 | 卡利拉制药公司 | 双环烷基化合物及合成 |
| EP3114107B1 (en) | 2014-03-07 | 2020-07-22 | Recurium IP Holdings, LLC | Propellane derivates and synthesis |
| TR201906040T4 (tr) | 2014-08-01 | 2019-05-21 | Glenmark Pharmaceuticals Sa | Bir mPGES-1 inhibitörü içeren nanopartikülat formülasyon. |
| EP3193855B1 (en) | 2014-09-17 | 2021-05-19 | Recurium IP Holdings, LLC | Bicyclic compounds |
| WO2017160922A1 (en) * | 2016-03-16 | 2017-09-21 | Kalyra Pharmaceuticals, Inc. | Analgesic compounds |
| WO2017160926A1 (en) * | 2016-03-16 | 2017-09-21 | Kalyra Pharmaceuticals, Inc. | Analgesic compounds |
| EP3628043A4 (en) | 2017-05-15 | 2021-04-28 | Recurium IP Holdings, LLC | ANALGESIC COMPOUNDS |
| SG11202003743SA (en) | 2017-11-22 | 2020-06-29 | Khondrion Ip B V | Compounds as mpges-1 inhibitors |
| HRP20230243T1 (hr) | 2018-06-07 | 2023-04-14 | Idorsia Pharmaceuticals Ltd | Alkoksi supstituirani derivati piridinila kao antagonisti receptora lpa1 i njihova uporaba u liječenju fibroze |
| AR119162A1 (es) | 2019-06-18 | 2021-12-01 | Idorsia Pharmaceuticals Ltd | Derivados de piridin-3-ilo |
| WO2021110805A1 (en) | 2019-12-04 | 2021-06-10 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
| WO2024029819A1 (ko) * | 2022-08-01 | 2024-02-08 | 경희대학교 산학협력단 | 벤즈이미다졸 유도체 또는 이의 약학적으로 허용되는 염을 함유하는 약학적 조성물 및 이의 제조방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050124638A1 (en) * | 2003-12-08 | 2005-06-09 | Swayze Eric E. | Benzimidazoles and analogs thereof as antivirals |
| JP5086809B2 (ja) | 2004-12-17 | 2012-11-28 | メルク カナダ インコーポレイテッド | ｍＰＧＥＳ−１阻害剤としての２−（フェニルまたはヘテロ環式）−１Ｈ−フェナントロ［９，１０−ｄ］イミダゾール |
| US7442716B2 (en) | 2004-12-17 | 2008-10-28 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors |
| UY32138A (es) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
| UY32470A (es) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
-
2011
- 2011-10-26 TW TW100138857A patent/TW201305178A/zh unknown
- 2011-10-28 US US13/283,786 patent/US8519149B2/en not_active Expired - Fee Related
- 2011-10-28 AR ARP110104018A patent/AR083610A1/es unknown
- 2011-10-28 WO PCT/EP2011/068967 patent/WO2012055995A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20120108583A1 (en) | 2012-05-03 |
| TW201305178A (zh) | 2013-02-01 |
| WO2012055995A1 (en) | 2012-05-03 |
| US8519149B2 (en) | 2013-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR083610A1 (es) | COMPUESTOS TRICICLICOS COMO INHIBIDORES DE PROSTAGLANDINA E SINTASA-1 MICROSOMICA (mPGES-1) | |
| UY30183A1 (es) | Derivados de quinolina | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
| AR061815A1 (es) | Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento | |
| EA201001683A1 (ru) | Производные фенил- или пиридинилзамещенных индазолов | |
| PE20181496A1 (es) | Inhibidores de ferroportina novedosos | |
| JP2014525420A5 (es) | ||
| AR082799A1 (es) | Derivados de quinolina y quinoxalina como inhibidores de quinasa | |
| EA201492214A1 (ru) | Ингибиторы вируса гепатита с | |
| MD20140072A2 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| MD4490B1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| AR054612A1 (es) | Derivados de espiroquetas y composiciones farmaceuticas para su utilizacion como agente terapeutico para diabetes | |
| MX2014012695A (es) | Derivados de isoindolona. | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| EA201300684A1 (ru) | Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1 | |
| EA201170772A1 (ru) | Органические соединения | |
| GEP20084452B (en) | Sulfonamide derivatives for the treatment of diseases | |
| MX2012007536A (es) | Derivados de heteroarilo que contienen nitrogeno. | |
| CO6351734A2 (es) | Compuestos de amida utiles en terapia | |
| GEP201706778B (en) | Pyridinyl and fused pyridinyl triazolone derivatives | |
| TW200612936A (en) | Indole derivatives | |
| AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento | |
| UA117020C2 (uk) | Нові сполуки індолу і піролу, спосіб їх одержання і фармацевтичні композиції, що їх містять | |
| ATE430744T1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |